Description
TOLVAPTAN. THIS MOD P0002 ADDS BACK FUNDS FOR 4TH DOSE TO BE INVOICED AND CLOSE OUT ORDER.
Base award description: TOLVAPTAN
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2020-01-31+$40,409= $40,409
- Mod P000012020-12-22-$10,102= $30,307
- Mod P000022022-09-07+$10,102= $40,409
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2020-01-31 | +$40,409 | $40,409 | TOLVAPTAN |
| Mod P00001· FUNDING ONLY ACTION | 2020-12-22 | −$10,102 | $30,307 | TOLVAPTAN |
| Mod P00002· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2022-09-07 | +$10,102 | $40,409 | TOLVAPTAN. THIS MOD P0002 ADDS BACK FUNDS FOR 4TH DOSE TO BE INVOICED AND CLOSE OUT ORDER. |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI EBASWPM7BVB8)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24226P0262 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $13,243 | FY2026 |
| 36C24226P0199 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $13,243 | FY2026 |
| 36C24226P0033 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $13,243 | FY2026 |
| 36C24225P1476 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $13,243 | FY2025 |
| 36C24225P1475 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $13,243 | FY2025 |
| 36C24225P1301 | 242-NETWORK CONTRACT OFFICE 02 (36C242) · 6505 · DRUGS AND BIOLOGICALS | $13,243 | FY2025 |
Other recipients under 6505 from 261-NETWORK CONTRACT OFFICE 21 (36C261) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26126P1178 | OPTUM FRONTIER THERAPIES II, LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $58,374 | FY2026 |
| 36C26126P1102 | ENVIGO RMS LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $74,586 | FY2026 |
| 36C26126P0961 | 10X GENOMICS, INC. | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $34,600 | FY2026 |
| 36C26126P0997 | SIERRA RADIOPHARMACY LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $247,204 | FY2026 |
| 36C26126P1008 | OPTUM FRONTIER THERAPIES II, LLC | 261-NETWORK CONTRACT OFFICE 21 (36C261) | $58,374 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_36C26120P0495_3600_-NONE-_-NONE- · retrieved 2026-09-26.